Majdee Islam, MD
Urology · Saint Peters, MONPI 1447645304
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (31.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Endo USA, Inc. accounts for 66.9% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $42,730, more than ten times the $1,087 reported in 2019. Among urology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $174.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo USA, Inc.$43K
- Coloplast$8K
- Boston Scientific$7K
- Endo Pharmaceuticals Inc.$1K
- Olympus Winter & Ibe GmbH$1K
- Verathon Inc.$875
- plus $3K from 27 others
Across 3 payments — averaging $858.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$2K
- US Endoscopy$950
What the payments were for
- Consulting fees$17,94528%
- Speaking & faculty fees$20,17031%
- Grants$5,1108%
- Travel & lodging$9,01114%
- Food & beverage$12,06219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo USA, Inc. | 82 | $42,986 |
| Coloplast | 30 | $8,036 |
| Boston Scientific | 128 | $6,932 |
| Endo Pharmaceuticals Inc. | 42 | $1,431 |
| Olympus Winter & Ibe GmbH | 2 | $1,375 |
| Verathon Inc. | 1 | $875 |
| Antares Pharma, Inc. | 24 | $777 |
| Urogen Pharma, Inc. | 4 | $299 |
| Accord Healthcare, Inc. | 3 | $207 |
| Olympus America Inc. | 2 | $142 |
| Myriad Genetic Laboratories, Inc. | 7 | $136 |
| Teleflex LLC | 4 | $125 |
| Medtronic | 3 | $115 |
| Novartis | 5 | $107 |
| Tolmar, Inc. | 7 | $104 |
| Johnson & Johnson | 1 | $104 |
| Axonics, Inc. | 1 | $101 |
| Bayer | 3 | $53 |
| Procept Biorobotics Corporation | 2 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Astellas Pharma US Inc | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Baxter Healthcare | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Blue Earth Diagnostics | 1 | $16 |
| SRS Medical Systems, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$41,932
- ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE$1,375
- GENERAL ERECTILE DYSFUNCTION$1,244
- NPD Clinical Study$875
- TITAN$866
- AMS$755
- AMS 700 CXR RTE KIT$538
- GENERAL - THERAPIES$450
- TACTRA$400
- XYOSTED$391
- AdVance XP$155
- iTIND System$129
- AMS 700$123
- ZUSDURI$121
- JELMYTO$121
- SENSOR$112
- VIRTUE$106
- Erleada$104
- Axonics r-SNM System$101
How this compares
$64,298 in reported general payments places this provider in the 95th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyostedTestosterone Enanthate | 67 | $46,141 |
| Testosterone | 37 | $8,512 |
| Testosterone Cypionate | 84 | $1,861 |
| Tamsulosin Hcl | 87 | $1,010 |
| Finasteride | 34 | $285 |
| Betamethasone Valerate | 11 | $243 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $153 |
| Oxycodone Hcl | 29 | $132 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $88 |
| Anastrozole | 13 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Antares Pharma, Inc.Xyosted | $777 | $46,14167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 urology providers in Missouri.
Other urology in Saint Peters
- Jeffrey GlaserSaint Peters$39K
- Kimberly BerniSaint Peters$14K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Samuel KuykendallKansas City$141K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.